COMPANION: A Couple Intervention Targeting Cancer-related Fatigue (COMPANION)

COMPANION Study: A Pilot Trial Testing Couple Mindfulness-based Cognitive Behavioral Therapy Via Internet Targeting Cancer-related Fatigue [Workpackage 2]

Chronic cancer-related fatigue (CCRF) is a disturbing condition that persists in up to 25% of cancer patients after completion of treatment. While mindfulness-based interventions are effective in relieving CCRF, these typically target the patient alone. Growing evidence suggests that including partners and targeting the dyadic context can increase and broaden the interventions' efficacy. The proposed study is a pilot trial testing the acceptability and potential efficacy of a mindfulness intervention directed at couples.

Study Overview

• Status: Active, not recruiting
• Conditions: Neoplasms; Fatigue
• Intervention / Treatment: Behavioral: Samen Minder Moe (Dutch intervention name)

Detailed Description

This is a 1-arm pilot trial. Recruitment will take place via a hospital, the Helen Dowling Institute and self-referral. The target is to include 34 couples (i.e. 68 participants). All participating cancer patients and their partners will be allocated to the couple mindfulness-based cognitive behavioral therapy, provided via internet (couple eMBCT), called 'COMPANION' (in Dutch: 'Samen Minder Moe') Assessments include three questionnaires (i.e. before starting the intervention (T0), after completing the intervention (T1), and 1 month after T1 (T2)). The assessments include also weekly diaries during a period of 17-22 weeks. A subsample of patients (n ≈ 5) and partners (n ≈ 5) as well as the therapists providing the couple eMBCT will participate in final focus groups. The primary objectives of COMPANION study 2 are to determine the acceptability of the couple intervention and the potential efficacy for patient fatigue. Secondary objectives are to examine the feasibility of trial procedures and the potential working mechanisms of the couple intervention.

• Study Type: Interventional
• Enrollment (Estimated): 68
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Mariët Hagedoorn, PhD; Phone Number: +31 50 361 6662; Email: mariet.hagedoorn@umcg.nl
• Study Contact Backup: Name: Fabiola Müller, PhD; Email: f.muller@umcg.nl

Study Locations

• Netherlands
  • Bilthoven, Netherlands, 3723 MB
    • Helen Dowling Institute
  • Groningen, Netherlands, 9700 RB
    • University Medical Center Groningen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Only couples are eligible for participation. In order to be eligible, the couple must meet each of the following criteria:

1. The patient has received a cancer diagnosis (all malignancies will be included);
2. The patient completed cancer treatment with either curative or palliative intent ≥ 3 months earlier. Patients who currently receive hormone therapy are eligible;
3. The patient experiences severe levels of fatigue (score of ≥ 35 on the Checklist Individual Strength, subscale fatigue severity (CIS-fatigue));
4. The patient has been suffering from severe fatigue for ≥ 3 months (as self-reported by the patient);
5. The patient was ≥ 18 years old at disease onset;
6. The partner is ≥ 18 years old;
7. Both couple members live together;
8. Both couple members have good command of the Dutch language (checked implicitly during registration);
9. Both couple members have adequate computer literacy and have access to an internet-connected computer, laptop or tablet (based on self-report);
10. Both couple members agree to participate in the research.

Exclusion Criteria:

The couple will be excluded in case:

1. The patient is currently following an evidence-based therapy for CCRF (i.e. Cognitive-Behavioral Therapy, mindfulness-based therapy, exercising/physiotherapy) as self-reported at the (telephone) screening;
2. The patient suffers from a condition that can explain his/her fatigue and is potentially treatable (e.g. anemia);

3. The therapist decides, based on information collected during the intake session, that the intervention is not suitable for the couple. Criteria that will be considered include, but are not limited to:

   • presence of severe psychiatric morbidity such as suicidal ideation and/or psychosis (as assessed by the therapist at the intake session). Mild depression is not an exclusion criterion. A score of ≥ 20 on the Hospital Anxiety and Depression Scale (HADS) at T0 is considered indicative of depression. Therefore, if the patient or the partner scores ≥ 20, the therapist will determine at the intake whether the participant has suicidal ideation or suffers from other severe psychiatric morbidity. A participant (and thus the couple) will be excluded if, according to the therapist, that is the case;
   • presence of substance abuse, except for smoking.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: couple eMBCT; The couple eMBCT has nine sessions, takes 15-20 weeks, can be followed from home and will be supervised remotely by a trained therapist. Consistent with the original (patient-only) eMBCT, the couple eMBCT aims to change the patient's behavioral and cognitive reactions to fatigue and other cancer-related stressors. Couple eMBCT includes information for partners each session, the possibility for partners to perform exercises and one session specifically dedicated to the couple's mutual relationship and mindful communication about CCRF. Couples can determine themselves to which degree the partner is involved in the therapy.

Behavioral: Samen Minder Moe (Dutch intervention name); 'Samen Minder Moe' is a mindfulness-based cognitive behavioral therapy for cancer-related fatigue directed at couples.; Other Names: COMPANION; couple eMBCT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Potential efficacy on patient fatigue as assessed with the fatigue severity subscale of the Checklist Individual Strength (CIS-fatigue) from pre-intervention (T0) to 2 weeks post-intervention (T1)	Fatigue is assessed with the Checklist Individual Strength, subscale fatigue severity (CIS-fatigue) on T0 (pre-intervention) and T1 (approx. 2 weeks after intervention completion). Eight items are rated on a 7-point scale, measuring fatigue in the preceding 2 weeks. The scale score ranges between 8 and 56, with a higher score indicating a higher level of fatigue.; Change in patient fatigue. The change in fatigue from T0 to T1 is tested with a matched pairs t-test and according to the intention-to-treat principle.Benchmark: a statistically significant (p < .05) decrease in patient fatigue between T0 and T1.; Clinically relevant change in patient fatigue. Operationalized as a reduction on the CIS-fatigue from T0 to T1 of at least 6-points. Benchmark: ≥ 45% of patients score on T1 at least 6 points lower than on T0.	From the pre-intervention baseline assessment (Timepoint 0) to the post-intervention assessment, 2 weeks after intervention completion (Timepoint 1)
Acceptability of the couple eMBCT operationalized as intervention adherence	Operationalized as percentage of couples in which the patient completed the intervention and the partner did not drop out from it. Patients' intervention completion will be recorded in the therapist log and assessed by patient self-report. If either one satisfies the completion criterion, the couple will be considered as intervention completers. Benchmark: >= 60% of couples completed the intervention.	Throughout intervention completion, about 15-20 weeks per couple
Acceptability of the couple eMBCT operationalized as satisfaction with the intervention	Quantitatively operationalized as satisfaction with the dyadic approach and the intervention overall (score >= 5 indicates satisfaction, (couples only, not therapists) as assessed at T1, 2 weeks after intervention completion. Benchmark: >= 70% of patients and 70% of partners indicating on the T1 questionnaire to be satisfied.	Throughout intervention completion, about 15-20 weeks per couple

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of trial procedures operationalized as recruitment rate	Benchmark: Recruitment rate: ≥ 3 couples included per month, averaged across both recruitment strategies.	Throughout study conduction, i.e. during the (planned) total of 18 months of data collection
Feasibility of trial procedures operationalized as T1 and T2 assessment adherence rate	Benchmark: T1 and T2 adherence rate: ≥ 65% of patients and partners complete the T1 and ≥ 60% of patients and partners complete the T2 questionnaire.	Throughout study conduction, i.e. during the (planned) total of 18 months of data collection
Feasibility of trial procedures operationalized as diary adherence rate	Diary adherence rate: ≥ 65% of diaries completed (11-14 diaries) by both patients and partners.	Throughout study conduction, i.e. during the (planned) total of 18 months of data collection
Potential working mechanisms of couple eMBCT	Diary data will be analyzed to assess the intervention's potential working mechanisms, i.e. whether expected improvements in targeted variables co-occur with the expected reduction in patient fatigue. The putative mechanism variables are: affect, sleep, catastrophizing, partner communication, partner interactions, self-efficacy, mindfulness and closeness. Multilevel growth curve analysis will be applied to model the time slopes of the potential mechanisms and weekly fatigue over the entire diary period. A variable is interpreted as potential working mechanism in case the standardized covariance between the slope change factor for the outcome (fatigue) and that of the presumed mediator is significant (using a z-test where +/-1.96 is significant at the .05 level).	During diary period, 17-22 weeks

Collaborators and Investigators

• Sponsor: Mariët Hagedoorn
• Collaborators: Helen Dowling Institute
• Investigators: Principal Investigator: Mariët Hagedoorn, PhD, University Medical Center Groningen

Publications and helpful links

Helpful Links

• Study website (in Dutch)

Study record dates

Study Major Dates

• Study Start (Actual): September 21, 2022
• Primary Completion (Estimated): January 21, 2024
• Study Completion (Estimated): March 21, 2024

Study Registration Dates

• First Submitted: October 31, 2022
• First Submitted That Met QC Criteria: December 2, 2022
• First Posted (Actual): December 5, 2022

Study Record Updates

• Last Update Posted (Actual): July 25, 2023
• Last Update Submitted That Met QC Criteria: July 24, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Cancer; Behavioral intervention; Pilot; Chronic cancer-related fatigue; Mindfulness intervention; Dyadic intervention; Partners; Spouses
• Additional Relevant MeSH Terms: Fatigue
• Other Study ID Numbers: 202100817; KWF-12794 (Other Grant/Funding Number: Dutch Cancer Society); NL80201.042.22 (Other Identifier: CCMO register (ABR))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Collected quantitative IPD (questionnaires, diaries) can potentially be shared.
• IPD Sharing Time Frame: After study completion and publication of outcome data.
• IPD Sharing Access Criteria: The anonymized data that support the findings of this study will become available from the principle investigators upon reasonable request, including a data analysis plan and research questions. Permission for data sharing will be asked from the medical ethical commission.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No